Plasma long non-coding RNA BACE1 as a novel biomarker for diagnosis of Alzheimer disease

Overview of attention for article published in BMC Neurology, January 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (80th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

twitter: 4 X users

patent: 2 patents

Citations

dimensions_citation: 103 Dimensions

Readers on

mendeley: 92 Mendeley

Summary X Patents Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 9,299 followers.

RT @jvdesomp: While I’m a strong believer of testing (non-coding) RNA in body fluids, there is a big difference between statistical signifi…

18 Jan 2018

Reply Repost Favourite

While I’m a strong believer of testing (non-coding) RNA in body fluids, there is a big difference between statistical significance and clinical utility. The difference in BACE1 levels in AD are marginal, with small AUC. https://t.co/T0y1RvB8ri

18 Jan 2018

Reply Repost Favourite

Plasma long non-coding RNA BACE1 as a novel biomarker for diagnosis of Alzheimer disease. - PubMed - NCBI https://t.co/rxAxltrOYM

18 Jan 2018

Reply Repost Favourite

Plasma long non-coding RNA BACE1 as a novel biomarker for diagnosis of Alzheimer disease. https://t.co/qaNcEfSl05 https://t.co/vaLWJaLL49

11 Jan 2018

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.